Drug Trial News

RSS

Additional data demonstrates positive results of pridopidine drug on Total Functional Capacity

Positive results from additional analyses of PRIDE-HD and Open-HART trials with pridopidine published in a peer-reviewed journal, The Journal of Huntington's Disease.

17 Dec 2020

LOOP technique is an effective alternative for treating skin abscesses

The LOOP technique for incision and drainage (I&D) of abscesses in adults is a safe and effective alternative to the traditional I & D with packing and may offer an alternative to the standard regimen in the treatment of uncomplicated skin abscesses in pediatric patients.

17 Dec 2020

BAT advances COVID-19 vaccine candidate into phase-I clinical trial

The COVID-19 vaccine candidate (KBP-COVID-19; NCT04473690) will become one of a number of potential vaccines to have progressed beyond pre-clinical testing.

16 Dec 2020

New data shows encouraging results for patients with neuro-degenerative blinding eye disease

New data published in the Journal Science Translational Medicine shows encouraging results in a worldwide clinical trial for patients diagnosed with the neuro-degenerative blinding eye disease; Leber Hereditary Optic Neuropathy (LHON.)

16 Dec 2020

RedHill Biopharma announces promising preliminary results from opaganib study

TEL AVIV, Israel and RALEIGH, NC, December 15, 2020, RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced promising preliminary results from a preclinical study with opaganib.

15 Dec 2020

Phase 2 clinical trial at UCR to test first-in-class drug for treatment of stuttering

The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.

15 Dec 2020

Combination of baricitinib and remdesivir could benefit some COVID-19 patients

The combination of baricitinib, an anti-inflammatory drug, and remdesivir, an antiviral, reduced time to recovery for people hospitalized with COVID-19, according to clinical trial results published in the New England Journal of Medicine.

11 Dec 2020

First patient participates in immunotherapy trial despite COVID-19 pandemic

Since 2016, Bernard Thurman has undergone traditional treatments, experimental therapies and surgeries to counter the cancer within him, but nothing has successfully eradicated the disease.

11 Dec 2020

Combination therapy places no greater burden on early-stage breast cancer patients

Adding an immune checkpoint inhibitor to the standard chemotherapy regimen for patients with early-stage breast cancer places no greater burden on patients' ability to perform day-to-day activities than chemotherapy alone, new research by Dana-Farber/Brigham and Women's Cancer Center investigators shows.

10 Dec 2020

Interim analysis of phase 3 study shows excellent efficacy of SARS-CoV-2 vaccine

South African study data were used to evaluate the safety of the vaccine in the results just published, but not its efficacy [which refers to the percentage reduction of disease].

9 Dec 2020

New data shows abemaciclib continues to benefit high-risk, HR+, HER2-, early-stage breast cancer patients

Extended follow-up data from the phase III monarchE trial showed that adding the cyclin-dependent kinase (CDK) inhibitor abemaciclib (Verzenio) to standard adjuvant endocrine therapy continued to improve invasive disease-free survival (IDFS) among patients with high-risk, node-positive, early-stage, HR-positive, HER2-negative breast cancer, according to data presented at the 2020 San Antonio Breast Cancer Symposium, held Dec. 8-11.

9 Dec 2020

Interim results show Oxford COVID-19 vaccine protects against symptomatic disease

First full results from interim analysis confirm that the Oxford COVID-19 vaccine (AZD1222) has an acceptable safety profile and is efficacious against symptomatic COVID-19 disease, with no hospitalizations or severe disease reported in the COVID-19 vaccine group so far.

9 Dec 2020

UC Davis Health joins with Novavax to test a new experimental coronavirus vaccine

Despite the encouraging news of potentially successful COVID-19 vaccine trials, there is not yet an FDA-approved vaccine available. Research into other effective coronavirus vaccines continues, including at UC Davis Health.

8 Dec 2020

Novel antibody-drug conjugate shows 29% response rate in rare blood cancer

Early study data shows a 29% overall response rate, the favorable safety profile in blastic plasmacytoid dendritic cell neoplasm (BPDCN)

8 Dec 2020

Phase I/IIA open-label study presents encouraging results on hard-to-treat AML subtypes

Novel menin-KMT2A inhibitor appears to be safe and well-tolerated. FLT3 inhibitor plus low-dose chemotherapy shows promising efficacy and safety. Results represent encouraging news on hard-to-treat AML subtypes.

7 Dec 2020

Mount Sinai study shows strong immune response, durability of universal influenza virus vaccine

A vaccine that induces immune responses to a wide spectrum of influenza virus strains and subtypes has produced strong and durable results in early-stage clinical trials in humans, Mount Sinai researchers have found.

7 Dec 2020

The intranasal route of immunization may offer effective protection against SARS-CoV-2

Researchers at the School of Medicine, Washington University in Saint Louis, USA, showed that the intranasal route of immunization could provide a more efficient protection against SARS-CoV-2 compared to the intramuscular route (i.e. through ‘jabs’).

7 Dec 2020

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial.

6 Dec 2020

New antiviral drug completely suppresses SARS-CoV-2 transmission within 24 hours

Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours, researchers in the Institute for Biomedical Sciences at Georgia State University have discovered.

3 Dec 2020

The UK approves Pfizer vaccine for December 2020 roll out

The UK approves Pfizer vaccine and schedules phased vaccination process, commencing December 2020.

2 Dec 2020

Previous
1
...
61
62
63
64
65
66
67
...
1143
Next

Drug Trial News

Additional data demonstrates positive results of pridopidine drug on Total Functional Capacity

LOOP technique is an effective alternative for treating skin abscesses

BAT advances COVID-19 vaccine candidate into phase-I clinical trial

New data shows encouraging results for patients with neuro-degenerative blinding eye disease

RedHill Biopharma announces promising preliminary results from opaganib study

Phase 2 clinical trial at UCR to test first-in-class drug for treatment of stuttering

Combination of baricitinib and remdesivir could benefit some COVID-19 patients

First patient participates in immunotherapy trial despite COVID-19 pandemic

Combination therapy places no greater burden on early-stage breast cancer patients

Interim analysis of phase 3 study shows excellent efficacy of SARS-CoV-2 vaccine

New data shows abemaciclib continues to benefit high-risk, HR+, HER2-, early-stage breast cancer patients

Interim results show Oxford COVID-19 vaccine protects against symptomatic disease

UC Davis Health joins with Novavax to test a new experimental coronavirus vaccine

Novel antibody-drug conjugate shows 29% response rate in rare blood cancer

Phase I/IIA open-label study presents encouraging results on hard-to-treat AML subtypes

Mount Sinai study shows strong immune response, durability of universal influenza virus vaccine

The intranasal route of immunization may offer effective protection against SARS-CoV-2

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

New antiviral drug completely suppresses SARS-CoV-2 transmission within 24 hours

The UK approves Pfizer vaccine for December 2020 roll out

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News